RLAY
Relay Therapeutics Inc

1,109
Mkt Cap
$1.26B
Volume
1.92M
52W High
$7.64
52W Low
$1.78
PE Ratio
-3.75
RLAY Fundamentals
Price
$7.34
Prev Close
$7.31
Open
$7.25
50D MA
$5.10
Beta
1.82
Avg. Volume
1.67M
EPS (Annual)
-$2.36
P/B
1.89
Rev/Employee
$38,341.00
Loading...
Loading...
News
all
press releases
Wall Street Analysts Think Relay Therapeutics (RLAY) Could Surge 86.05%: Read This Before Placing a Bet
The consensus price target hints at an 86.1% upside potential for Relay Therapeutics (RLAY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·9h ago
News Placeholder
More News
News Placeholder
Here's Why Relay Therapeutics, Inc. (RLAY) is a Great Momentum Stock to Buy
Does Relay Therapeutics, Inc. (RLAY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·2d ago
News Placeholder
3 Cancer-Focused Stocks Showing Strong Pipeline Progress
Relay, Fate and Verastem advance promising cancer therapies, strengthening their pipelines in a rapidly evolving oncology market.
Zacks·2d ago
News Placeholder
Wall Street Analysts Believe Relay Therapeutics (RLAY) Could Rally 116.91%: Here's is How to Trade
The mean of analysts' price targets for Relay Therapeutics (RLAY) points to an 116.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·16d ago
News Placeholder
Investing in Oncology: 3 Cancer Stocks With Promising Pipelines
Relay Therapeutics, Pyxis Oncology and Allogene Therapeutics drive cancer innovation with pivotal trials and promising drug candidates.
Zacks·2mo ago
News Placeholder
Relay Therapeutics (RLAY) Upgraded to Buy: What Does It Mean for the Stock?
Relay Therapeutics (RLAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·3mo ago
News Placeholder
Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Beats Revenue Estimates
Relay Therapeutics (RLAY) delivered earnings and revenue surprises of +16.33% and +35.40%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now?
Recursion Pharmaceuticals and Relay Therapeutics both leverage their respective AI drug discovery platforms to potentially develop novel therapeutic candidates.
Zacks·3mo ago
News Placeholder
Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses?
Recursion Pharmaceuticals bets on REC-4881, cancer candidates and new hypophosphatasia therapy to rebuild momentum after key drug cuts rattled investors.
Zacks·3mo ago
News Placeholder
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
RXRX is scaling its AI-driven drug discovery technology through billion-dollar pharma deals and strategic tech alliances.
Zacks·4mo ago

Latest RLAY News

View

Advertisement|Remove ads.

Advertisement|Remove ads.